MS-Docblog

News from the AAN 2015 on PPMS

20. May 2015 Prof. Dr. med. Mathias Mäurer Therapy for MS

At the end of April, I had the opportunity to attend the annual meeting of the American Academy of Neurology (AAN) – the largest annual neurological congress where more than 10,000 neurologists and neuroscientists meet.

Lemtrada

8. May 2015 Prof. Dr. med. Mathias Mäurer Therapy for MS

For more than a year, the monoclonal antibody Lemtrada® (Alemtuzumab) has been approved in Germany for the treatment of relapsing MS. Although the study data indicates it is a very effective MS therapy, the drug

Sport and MS

1. May 2015 Prof. Dr. med. Mathias Mäurer Complementary Medicine

I have a number of MS patients for whom I am convinced that their lack of physical and mental capacity is largely due to lack of fitness and secondary diseases based on this.

Tysabri – There is No 2-Year Limit for Therapy

24. April 2015 Prof. Dr. med. Mathias Mäurer MS Therapy

“Tysabri® can only be given for 2 years.” – I hear this sentence quite often, and it is definitely not correct! Natalizumab can ultimately be given lifelong, or – perhaps more realistically formulated – Tysabri®

“Can’t I do more…”

16. April 2015 Prof. Dr. med. Mathias Mäurer General

In consultation discussions about MS, patients often ask me what they can do in addition to taking prophylactic medication. In this context, questions about special diets or specific behaviors in everyday life are often asked.

MS Therapy 2015 – Expectations and Possibilities

2. April 2015 Prof. Dr. med. Mathias Mäurer Therapy for MS

Our opportunities in MS therapy have changed and improved significantly over the last 20 years. In the 90s of the last century, the goal of administering MS drugs was to delay the natural course of

Uhthoff’s Phenomenon – What is it?

20. March 2015 Prof. Dr. med. Mathias Mäurer MS Symptoms

Actually, this phenomenon should be known to almost every MS patient – because it is very common. Surprisingly, however, I also find again and again that knowledge about this is not widespread.

Therapy Goals

13. March 2015 Prof. Dr. med. Mathias Mäurer Therapy for MS

The 32-year-old engineer was diagnosed with MS at the age of 25. From my perspective, everything initially went quite smoothly: The diagnosis was made directly after the first event and an immunotherapy was initiated. Back

First PML Case under Tecfidera

6. March 2015 Prof. Dr. med. Mathias Mäurer General

This case is not exactly new – to be precise, the news came out in October 2014 – nevertheless, I keep hearing inquiries about the situation, which is why I would like to briefly comment

What is PML actually?

24. February 2015 Prof. Dr. med. Mathias Mäurer General

As neurologists, we are well familiar with the term “PML”. In fact, I almost have to be grateful that a patient recently asked me quite sincerely what it actually is.

News from the AAN 2015 on PPMS

Lemtrada

Sport and MS

Tysabri – There is No 2-Year Limit for Therapy

“Can’t I do more…”

MS Therapy 2015 – Expectations and Possibilities

Uhthoff’s Phenomenon – What is it?

Therapy Goals

First PML Case under Tecfidera

What is PML actually?

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community